[Clinical trial with barbexaclone in epilepsies].
A open clinic assay with barbexaclone which is an association of phenobarvital with light stimulant of the central nervous system (tau-l-ciclohexil-2-methil-aminopropane) for the treatment of epileptic disorders is reported. The authors have studied 40 patients aged between 0-12 years of age, of both sexes, all of them having convulsive seizures of the Grand Mal type associated or not to other epileptic manifestations. After analysing the different aspects of the group they consider satisfactory the results obtained: very good or good in 82,5% of the cases.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010634:Phenobarbital / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D004338:Drug Combinations; D011437:Propylamines; C011019:barbexaclone; D010634:Phenobarbital
Ensaio clinico com barbexaclone nas epilepsias